viernes, 29 de junio de 2018

Treatment Regimens for Latent TB Infection | Treatment | TB | CDC

Treatment Regimens for Latent TB Infection | Treatment | TB | CDC

Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People



Treatment Regimens for Latent TB Infection (LTBI)



The four treatment regimens for latent TB infection (LTBI) use isoniazid (INH), rifapentine (RPT), or rifampin (RIF). While all the regimens are effective, healthcare providers should prescribe the more convenient shorter regimens, when possible. Patients are more likely to complete shorter treatment regimens.
Treatment must be modified if the patient is a contact of an individual with drug-resistant TB disease. Consultation with a TB expert is advised if the known source of TB infection has drug-resistant TB.
CDC has updated the recommendations for use of once-weekly isoniazid-rifapentine for 12 weeks (3HP) for treatment of latent TB infection.
Latent TB Infection Treatment Regimens
Latent TB Infection Treatment Regimens 
DrugsDurationIntervalComments
Isoniazid and Rifapentine3 monthsOnce weekly*Not recommended for persons who are:
  • Less than 2 years old,
  • Living with HIV/AIDS and taking antiretroviral medications with clinically significant or unknown drug interactions with rifapentine,
  • Presumed infected with INH- or RIF-resistant M. tuberculosis, and
  • Women who are pregnant or expect to become pregnant within the 12 week regimen.
Rifampin4 monthsDailyNot recommended for persons who are:
  • Living with HIV/AIDS and taking antiretroviral medications with clinically significant or unknown drug interactions with rifampin (rifabutin may be used as a substitute),
  • Presumed infected with RIF-resistant M. tuberculosis, and
  • Women who are pregnant or expect to become pregnant within the 4 month regimen.
Isoniazid6 monthsDailyNot recommended for persons who are presumed infected with INH-resistant M. tuberculosis.
Twice weekly**Not recommended for persons who are presumed infected with INH-resistant M. tuberculosis.
Isoniazid9 monthsDailyNot recommended for persons who are presumed infected with INH-resistant M. tuberculosis.

Preferred treatment for:
  • Persons living with HIV AIDS and taking antiretroviral medications with clinically significant or unknown drug interactions with once-weekly rifapentine or daily rifampin,
  • Pregnant women (with pyridoxine/vitamin B6 supplements)
Twice weekly**Not recommended for persons who are presumed infected with INH-resistant M. tuberculosis.

Preferred treatment for pregnant women (with pyridoxine/vitamin B6 supplements)
*Use Directly Observed Therapy (DOT) or Self-Administered Therapy (parentally-administered SAT to children)
**Use Directly Observed Therapy (DOT)
Note: Due to the reports of severe liver injury and deaths, CDC recommends that the combination of rifampin (RIF) and pyrazinamide (PZA) should not be offered for the treatment of latent TB infection.




Related Links


For Patients

For Health Care Providers

No hay comentarios:

Publicar un comentario